Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This was a single-arm, prospective study to investigate the safety of cetuximab in
combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese
patients with RAS wild-type mCRC.